Gabelli Funds LLC Trims Stake in Steris Plc (STE)
Gabelli Funds LLC lowered its holdings in shares of Steris Plc (NYSE:STE) by 1.1% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 53,500 shares of the company’s stock after selling 584 shares during the quarter. Gabelli Funds LLC owned approximately 0.06% of Steris Plc worth $4,729,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in STE. Citigroup Inc. purchased a new stake in shares of Steris Plc during the 2nd quarter valued at about $206,000. Van Cleef Asset Management Inc purchased a new stake in Steris Plc in the 2nd quarter worth approximately $208,000. Cigna Investments Inc. New bought a new position in Steris Plc in the 2nd quarter worth approximately $209,000. BT Investment Management Ltd bought a new position in Steris Plc in the 2nd quarter worth approximately $210,000. Finally, Allegis Investment Advisors LLC bought a new position in Steris Plc in the 2nd quarter worth approximately $251,000. 93.50% of the stock is owned by hedge funds and other institutional investors.
In other Steris Plc news, VP Karen L. Burton sold 3,270 shares of the company’s stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of C$85.70, for a total transaction of C$280,239.00. Following the sale, the vice president now owns 11,807 shares in the company, valued at approximately C$1,011,859.90. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Walter M. Rosebrough, Jr. sold 10,000 shares of the company’s stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of C$85.69, for a total value of C$856,900.00. Following the sale, the chief executive officer now owns 83,270 shares in the company, valued at approximately C$7,135,406.30. The disclosure for this sale can be found here. In the last ninety days, insiders sold 202,342 shares of company stock worth $17,729,692. Corporate insiders own 2.55% of the company’s stock.
Several research firms have weighed in on STE. TD Securities upped their price target on Steris Plc from C$14.00 to C$16.00 and gave the stock a “buy” rating in a research note on Thursday. Raymond James Financial, Inc. increased their target price on Steris Plc from $95.00 to $100.00 and gave the company an “outperform” rating in a research report on Monday, October 16th. BidaskClub downgraded Steris Plc from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Zacks Investment Research downgraded Steris Plc from a “buy” rating to a “sell” rating in a research report on Monday, November 6th. Finally, KeyCorp restated an “overweight” rating and issued a $101.00 price target (up from $91.00) on shares of Steris Plc in a research report on Thursday, November 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. Steris Plc currently has an average rating of “Hold” and an average target price of C$77.80.
Shares of Steris Plc (STE) opened at C$86.85 on Monday. The company has a current ratio of 2.80, a quick ratio of 2.18 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $7,386.80, a PE ratio of 22.38 and a beta of 1.31. Steris Plc has a twelve month low of C$64.37 and a twelve month high of C$93.39.
Steris Plc (NYSE:STE) last posted its quarterly earnings data on Wednesday, November 1st. The company reported C$0.94 EPS for the quarter, missing the Zacks’ consensus estimate of C$0.95 by C($0.01). Steris Plc had a net margin of 5.59% and a return on equity of 11.49%. The business had revenue of C$634.20 million during the quarter, compared to analysts’ expectations of C$629.02 million. During the same quarter last year, the firm earned $0.89 earnings per share. The firm’s quarterly revenue was down 1.9% compared to the same quarter last year. analysts expect that Steris Plc will post 4.06 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 20th. Stockholders of record on Wednesday, November 22nd will be paid a $0.31 dividend. This represents a $1.24 annualized dividend and a dividend yield of 1.43%. The ex-dividend date of this dividend is Tuesday, November 21st. Steris Plc’s dividend payout ratio (DPR) is presently 73.81%.
Steris Plc Company Profile
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Steris Plc (NYSE:STE).
Receive News & Ratings for Steris Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.